Genentech's Karen Massey to join argenx as COO

Dutch autoimmune diseases specialist argenx (Euronext & Nasdaq: ARGX) said today that Karen Massey will join the company as chief operating officer COO, effective March 13, 2023.

Ms Massey will succeed Keith Woods, who will remain at argenx for a transition period to support the launch of subcutaneous efgartigimod, after which he will retire and serve as a strategic advisor on the commercial committee of the argenx board of directors.

Ms Massey has over 20 years’ experience in the pharmaceutical and biotechnology industry with an impressive breadth of experience across commercial, product development, corporate strategy and innovation. She joins argenx from Genentech, a subsidiary of Swiss pharma giant Roche (ROG: SIX), where she most recently served as senior vice president of product development and global clinical operations. In this capacity, she led a global organization of more than 2,000 people across 24 countries and was accountable for operationalizing over 300 clinical trials within oncology, neuroscience, infectious diseases, immunology and ophthalmology.